Lucid Diagnostics prices $18M underwritten offering of 18M shares at $1.00 per share

Lucid Diagnostics Inc.

Offering of 18,000,000 common shares at $1.00 each; gross proceeds ~$18M.
Underwriters purchase at $0.94/share; net proceeds for working capital and general corporate purposes.
Anchored by a $15M investment from a fundamental institutional investor and support from a large existing shareholder.
Closing expected on or about April 24, 2026, subject to customary conditions.
Canaccord Genuity and BTIG act as joint bookrunners; shelf registration effective March 26, 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lucid Diagnostics Inc. entered into Underwriting Agreement with Canaccord Genuity LLC and BTIG, LLC, as representatives of the underwriters (effective 2026-04-23).

Action: entry
Agreement: underwriting
Counterparty: Canaccord Genuity LLC and BTIG, LLC, as representatives of the underwriters
Effective: 2026-04-23

Exact text from the filing

On April 23, 2026, Lucid Diagnostics Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Canaccord Genuity LLC and BTIG, LLC, as representatives (the “ Representatives ”) of the underwriters named therein (the “ Underwriters ”), for an underwritten offering to the public of shares of the Company’s common stock

View on SEC.gov

Browse all material agreements →

Lucid Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-018725

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.